MedPath

A clinical trial to study the effect of Agnimukha Churna in patients with Udavartini Yoni Vyapad (Primary Dysmenorrhea) & compare the efficacy of this drug with Rajahpravartini Vati .

Phase 3
Not yet recruiting
Conditions
Primary dysmenorrhea. Ayurveda Condition: UDAVARTINI,
Registration Number
CTRI/2023/12/060751
Lead Sponsor
Chinmayi M S
Brief Summary

Many drugs are used for internal administration, external application and preventive measures havebeen described in Ayurveda Samhitas and modern science to overcome UDAVARTINI YONIVYAPAD/ Primary Dysmenorrhea. So a remedy which would be economical ,efficacious and benefits the largerscale of community. Therefore an attempt was made to study the clinical evaluation of Agnimukha Churna in the management of Udavartini yonivyapad and compare its efficacy with the Rajahpravartini vati.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • Patient fulfilling any of the following diagnostic criteria will be selected for the study.
  • Pain in the lower abdomen which begins one or two days before menstruation or with the onset of menstruation and lasting for few hours or one to two days.
  • Pain in the lower abdomen and suprapubic region, radiating to medial aspect of the thighs and lower back.
  • 3 .Painful menstruation also associated with symptoms like headache, fatigue, nausea, vomiting and constipation.
  • 4 .Age between 16 to 30 years 5.
  • Married or unmarried females 6.History of painful menstruation for at least 3 consecutive cycles 7.Patients with regular menstrual cycles (21 to 35 days).
Exclusion Criteria
  • 1.Cases of secondary dysmenorrhea with pelvic pathology – Fibroid uterus, endometriosis, Adenomyosis, AUB, PID, Ovarian cyst, cervicitis.
  • Patients with Congenital anomalies of Reproductive tract 3.Patients with systemic diseases like Diabetes Mellitus, Hypertension, Anaemia 4.Patients on Hormonal therapy, contraception and Intra uterine contraceptive device.
  • 5.Endocrinal disorders like thyroid abnormalities and PCOS 6.Surgical and Malignant conditions.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pain criteria will be assessed using VAS grading.4th day of each menstrual cycle for 3 consecutive cycles.
a)Intensity of pain4th day of each menstrual cycle for 3 consecutive cycles.
c)Pain associated with symptoms such as nausea, vomiting, headache, constipation & fatigue.4th day of each menstrual cycle for 3 consecutive cycles.
b)Site of pain4th day of each menstrual cycle for 3 consecutive cycles.
d)Duration of pain4th day of each menstrual cycle for 3 consecutive cycles.
e)Nature of pain4th day of each menstrual cycle for 3 consecutive cycles.
Secondary Outcome Measures
NameTimeMethod
a)Intensity of pain: VAS Scale: Mild / Moderate / Severeb)Site of pain: Lower abdomen & suprapubic region

Trial Locations

Locations (1)

Alvas Ayurveda College And Hospital , Moodbidri

🇮🇳

Kannada, KARNATAKA, India

Alvas Ayurveda College And Hospital , Moodbidri
🇮🇳Kannada, KARNATAKA, India
Chinmayi M S
Principal investigator
9663510951
drchinmayims@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.